Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Wajant, Jeannette Gerspach, K. Pfizenmaier (2005)
Tumor therapeutics by design: targeting and activation of death receptors.Cytokine & growth factor reviews, 16 1
L. Lincz (1998)
Deciphering the apoptotic pathway: All roads lead to deathImmunology and Cell Biology, 76
M. Maemondo, Y. Saijo, K. Narumi, T. Kikuchi, K. Usui, R. Tazawa, Kunio Matsumoto, Toshikazu Nakamura, K. Sasaki, Minoru Takahashi, Y. Niitsu, T. Nukiwa (2004)
Gene Therapy with Secretory Leukoprotease Inhibitor Promoter-Controlled Replication-Competent Adenovirus for Non-Small Cell Lung CancerCancer Research, 64
Heidi Leblanc, A. Ashkenazi (2003)
Apo2L/TRAIL and its death and decoy receptorsCell Death and Differentiation, 10
F. Jin, C. Nathan, D. Radzioch, A. Ding (1997)
Secretory Leukocyte Protease Inhibitor: A Macrophage Product Induced by and Antagonistic to Bacterial LipopolysaccharideCell, 88
N. Shine, K. Konopka, N. Düzgüneş (1997)
Concise Review: The Anti-HIV-1 Activity Associated with SalivaJournal of Dental Research, 76
S. Tsukishiro, N. Suzumori, H. Nishikawa, A. Arakawa, K. Suzumori (2005)
Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis.Gynecologic oncology, 96 2
K. Burvall, L. Palmberg, K. Larsson (2005)
Expression of TNFalpha and its receptors R1 and R2 in human alveolar epithelial cells exposed to organic dust and the effects of 8-bromo-cAMP and protein kinase A modulationInflammation Research, 54
R. Kelley, K. Totpal, Stephanie Lindstrom, M. Mathieu, K. Billeci, L. Deforge, R. Pai, S. Hymowitz, A. Ashkenazi (2005)
Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis Signaling*Journal of Biological Chemistry, 280
C. Franken, C Meijer, J. Dijkman (1989)
Tissue distribution of antileukoprotease and lysozyme in humans.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 37
S. Ibrahim, J. Ringel, C. Schmidt, B. Ringel, P. Müller, D. Koczan, H. Thiesen, M. Löhr (2001)
Pancreatic Adenocarcinoma Cell Lines Show Variable Susceptibility to TRAIL-Mediated Cell DeathPancreas, 23
C. Boudier, M. Cadene, J. Bieth (1999)
Inhibition of neutrophil cathepsin G by oxidized mucus proteinase inhibitor. Effect of heparin.Biochemistry, 38 26
G. Ashcroft, K. Lei, W. Jin, G. Longenecker, A. Kulkarni, T. Greenwell-Wild, H. Hale‐Donze, G. McGrady, Xiao-yu Song, S. Wahl (2000)
Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healingNature Medicine, 6
A. Lentsch, J. Jordan, B. Czermak, K. Diehl, E. Younkin, V. Sarma, P. Ward (1999)
Inhibition of NF-κB Activation and Augmentation of IκBβ by Secretory Leukocyte Protease Inhibitor during Lung InflammationAmerican Journal of Pathology, 154
E. Stylianou, A. Yndestad, L. Sikkeland, V. Bjerkeli, J. Damås, T. Haug, H. Eiken, P. Aukrust, S. FrØLand (2002)
Effects of interferon‐α on gene expression of chemokines and members of the tumour necrosis factor superfamily in HIV‐infected patientsClinical & Experimental Immunology, 130
E. Stylianou, A. Yndestad, L. Sikkeland, V. Bjerkeli, J. Damås, T. Haug, H. Eiken, P. Aukrust, S. Frøland (2002)
Effects of interferon-alpha on gene expression of chemokines and members of the tumour necrosis factor superfamily in HIV-infected patients.Clinical and experimental immunology, 130 2
P. Henriksen, M. Hitt, Z. Xing, Jun Wang, C. Haslett, R. Riemersma, D. Webb, Y. Kotelevtsev, J. Sallenave (2004)
Macrophages to Atherogenic Stimuli Responses of Human Endothelial Cells and B-Dependent Inflammatory κ Attenuates NF-Secretory Leukocyte Protease Inhibitor Adenoviral Gene Delivery of Elafin and Kotelevtsev and
T. Griffith, D. Lynch (1998)
TRAIL: a molecule with multiple receptors and control mechanisms.Current opinion in immunology, 10 5
P. Ward, A. Lentsch (2004)
Endogenous regulation of the acute inflammatory responseMolecular and Cellular Biochemistry, 234-235
S. Nagata (1997)
Apoptosis by Death FactorCell, 88
A. King, D. Fleming, H. Critchley, R. Kelly (2002)
Regulation of natural antibiotic expression by inflammatory mediators and mimics of infection in human endometrial epithelial cells.Molecular human reproduction, 8 4
D. Rein, M. Breidenbach, T. Kirby, Tie Han, G. Siegal, G. Bauerschmitz, Minghui Wang, D. Nettelbeck, Y. Tsuruta, Masato Yamamoto, P. Dall, A. Hemminki, D. Curiel (2005)
A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 11 3
J. Steffens, P. Dijkman, R. Hiemstra, J. Maassen, R. Stolk, G. Heinzel-Wieland (1995)
Copyright � 1996, American Society for Microbiology Antibacterial Activity of Antileukoprotease
(2003)
Murine macrophages producesecretory leukocyte protease inhibitor during clearance of apoptotic cells : implications for resolution of the inflammatory response
T. Abe, Nobuyuki Kobayashi, Kunihiko Yoshimura, Bruce Trapnell, Haimee Kim, R. Hubbard, T. Michael, Brewer, C. Robert, Thompson, Ronald Crystal (1991)
Expression of the secretory leukoprotease inhibitor gene in epithelial cells.The Journal of clinical investigation, 87 6
Fenyu Jin, C. Nathan, D. Radzioch, A. Ding (1998)
Lipopolysaccharide-Related Stimuli Induce Expression of the Secretory Leukocyte Protease Inhibitor, a Macrophage-Derived Lipopolysaccharide InhibitorInfection and Immunity, 66
In light of the poor prognosis for ovarian cancer, research continues for innovative and efficacious treatment modalities. It is now widely accepted that new approaches for the treatment of ovarian cancers are pivotal in further improving prognosis of this disease. Secretory leukoprotease inhibitor (SLPI) is an 11.7-kDa non-glycosylated, serine protease inhibitor that has a broad inhibitory spectrum against serine protease. SLPI showed potential therapeutic inhibitory effects mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TNF-α, death receptor (DR)-4, DR-5 and TNF receptor (TNFR)-I expression which lead to an activation of apoptosis pathway through Caspase-2, Caspase-8 and Caspase-9. We examined whether levels of SLPI protein expression correlated with clinicopathological characteristics in 58 ovarian cancer samples, and investigated the role of SLPI and its biological functions. SLPI expression showed a significant correlation between low expression of SLPI and amount of ascites (p=0.021), lymph node metastasis (p=0.011). We propose that SLPI could be considered a therapeutic target for the treatment of ovarian cancer.
Oncology Reports – Spandidos Publications
Published: May 1, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.